Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax
and how well they work in treating patients with solid tumors that have spread to other
places in the body (advanced or metastatic). Trametinib and navitoclax may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.